Company: BDRX
Filing Date: 2025-09-26
Form Type: F-3
Source: 0001214659-25-014255
Chunk: 11

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-09-26
Form: F-3
Chunk 11
---
 product via convection-enhanced delivery at potentially chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and avoiding systemic toxicity. We completed recruitment of the first cohort of patients in an ongoing Phase 1 study of MTX110 in recurrent glioblastoma. We have also completed and announced the results of two Phase 1 studies in DMG. Due to resource constraints, MTX110 has been de-prioritized.

Our clinical assets are supported by three proprietary drug delivery technologies focused on improving bio-delivery and bio-distribution of drugs through either sustained delivery (Q-Sphera TM), direct delivery (MidaSolve TM), or targeted delivery (MidaCore TM):

| · | Our Q-Sphera platform: Our disruptive polymer microsphere microtechnology                                                                
 is used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. |

| · | Our MidaSolve platform: Our innovative oligosaccharide nanotechnology                                         
 is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors. |

| 4 |

| · | MidaCore platform: Our gold nanoparticle nanotechnology is used                                     
 for targeting sites of disease by using either chemotherapeutic agents or immunotherapeutic agents. |

We are currently focused on
our clinical stage assets eRapa and tolimidone and there are no active research and development programs based on our drug delivery technologies.

<div align='center'>Additional Information</div>

For additional information related to our business and operations,
please refer to the reports incorporated herein by reference, including the Annual Report on Form 20-F of Biodexa Pharmaceuticals PLC
for the year ended December 31, 2024 and the Reports on Form 6-K furnished with the SEC, as described under the caption “Incorporation
of Documents by Reference” on page 62 of this prospectus.

<div align='center'>Our Corporate Information</div>

We are a public limited company
incorporated under the laws of England and Wales under registered number 09216368. Our principal executive offices are located at 1 Caspian
Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. The telephone number at our principal executive office is +44 29 20480 180. Our
authorized representative in the United States is Donald J. Puglisi of